icostatistics
Posts
Publications
M.-K.A. Ljoså
Latest
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Cite
×